CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest ... that are hired by employers to oversee prescription coverage for Americans.

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss ... patients cannot afford to pay for on their own. The formulary is maintained by CVS ...

The S&P 500 climbed by 2.8% on Monday, May 12, 2025 as investors reviewed the trade deal between the U.S. and China that ...

Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

The data is the first head-to-head trial comparing the wildly popular medicines, and gives Lilly more firepower as it seeks ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

A measure now on the floor of the Nebraska Legislature would address some practices by intermediaries called pharmacy benefit managers that pharmacists say are harming their businesses.

Boards, Policy & Regulationcategory· May 12, 2025 Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in ... Lilly downplays CVS move to drop Zepbound coverage, shares plunge ...

Oscar Health CEO Mark Bertolini has helped lead the insurance tech company into a period of consistent profitability after ...